ENRUHE
PF-Atlas › Clinical Trials › NCT01069705

Second Open Label Extension to Bridging Study CTBM100C2303

Tobramycin inhalation powder · Phase 3

Registry ID
NCT01069705
Phase
Phase 3
Status
Completed
Drug / intervention
Tobramycin inhalation powder
Sponsor
Novartis Pharmaceuticals
Start
2010-02-12

About this trial

Tobramycin inhalation powder is evaluated in NCT01069705, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Novartis Pharmaceuticals. Current status: Completed.

View NCT01069705 on ClinicalTrials.gov →

Explore related

All Tobramycin inhalation powder trialsAll IPF trials

Related trials

Tobramycin inhalation powder — NCT00982930Tobramycin Inhalation Powder — NCT01844778Tobramycin Inhalation Powder — NCT00125346
Medical disclaimer. This page summarizes public trial data for NCT01069705 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.